A notable advancement in diabetes care is emerging with the approval of tirzepatide at a dosage of 45mg. This innovative version builds upon the existing success of tirzepatide, a dual GIP and GLP-1 agonist, and https://deaconvjzv137414.wikirecognition.com/user